Credit Suisse plans accelerated barrier notes tied to biotech ETF

By Marisa Wong

Morgantown, W.Va., Nov. 11 – Credit Suisse AG, London Branch plans to price 0% accelerated barrier notes due Dec. 3, 2021 linked to the SPDR S&P Biotech exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.

If the fund finishes at or above its initial level, the payout at maturity will be par plus 100% to 110% of the gain.

If the fund falls but finishes at or above the 57.5% to 62.5% knock-in level, the payout will be par.

Otherwise, investors will be fully exposed to the decline in the fund.

Credit Suisse Securities (USA) LLC is the agent.

The notes will price on Nov. 30 and settle on Dec. 5.

The Cusip number is 22548QNE1.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.